JOINT HEALTH AND MOBILITY

Osteoarthritis, joint lesions and other muscular-skeletal disorders

One of our priorities is to improve the quality of life of the over 200 million patients in the world who suffer from osteoarthritis, joint lesions and muscular-skeletal disorders. Therefore, as well as Heparin, at Bioibérica we produce other biomolecules like Chondroitin Sulfate, Glucosamine, Hyaluronic Acid or Collagen, indicated for the treatment of these illnesses.

This specialization in joint health has contributed to being endorsed by numerous published clinical trials, ongoing research projects, the recognition of different scientific and medical societies, and the publication of specialized publications. Below you can consult our product portfolio:

We are the first European producer of Chondroitin Sulfate

Bioiberica researches, develops, manufactures and markets the main molecules for treating osteoarthiritis: chondroitin sulphate, glucosamine and hyaluronic acid.

Line of drugs issued on prescription for osteoarthritis

Chondroitin sulfate, glucosamine and hyaluronic acid are drugs that act directly on the joint structures affected by osteoarthritis.

Ingredients for nutritional supplements

Innovative range of branded ingredients, within the nutraceutics line, for the development of develop nutritional complements aimed at improving joint health.

Range aimed at improving joint health

Specific products for nourishing the affected joint tissue, such as tendons, ligaments, the synovial membrane and the subchondral bone.

Related news

Access to the press room